A Retrospective Database Analysis of Prescribing Patterns for Specific Angiotensin Receptor Blockers

Saira A. Jan, MS, PharmD; Jay V. Patel, PharmD; John Welz, MPH; Patricia Ishak, PharmD

In This Article


This analysis of claims data from a large managed care database demonstrated that significant variability exists in the frequency of dosing of ARB products. Because this therapeutic class contains many higher-cost antihypertensive agents, observed differences in DACON scores may have significant economic and design implications for health plans and managed care formularies. Variable ARB dosing potentially could also affect quality of care, in addition to overall costs.

However, these conclusions are limited by lack of clinical information. Further real-world evaluations of ARBs are warranted to address the impact of variations in utilization on clinical effectiveness.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.